Optimization of the biotechnological production of a novel class of anti-MRSA antibiotics from Chitinophaga sancti.

2.50
Hdl Handle:
http://hdl.handle.net/10033/621102
Title:
Optimization of the biotechnological production of a novel class of anti-MRSA antibiotics from Chitinophaga sancti.
Authors:
Beckmann, Amelie; Hüttel, Stephan; Schmitt, Viktoria; Müller, Rolf ( 0000-0002-1042-5665 ) ; Stadler, Marc ( 0000-0002-7284-8671 )
Abstract:
Recently, the discovery of the elansolids, a group of macrolides, was reported. The molecules show activity against methicillin-resistant Staphylococcus aureus as well as other gram-positive organisms. This fact renders those substances a promising starting point for future chemical development. The active atropisomers A1/A2 are formed by macrolactonization of the biosynthesis product A3 but are prone to ring opening and subsequent formation of several unwanted side products. Recently it could be shown that addition of different nucleophiles to culture extracts of Chitinophaga sancti enable the formation of new stable elansolid derivatives. Furthermore, addition of such a nucleophile directly into the culture led exclusively to formation of a single active elansolid derivative. Due to low product yields, methods for production of gram amounts of these molecules have to be established to enable further development of this promising compound class.
Affiliation:
Helmholtz-Zentrum für Infektionsforschung GmbH, Inhoffenstr. 7, 38124 Braunschweig, Germany.
Citation:
Optimization of the biotechnological production of a novel class of anti-MRSA antibiotics from Chitinophaga sancti. 2017, 16 (1):143 Microb. Cell Fact.
Journal:
Microbial cell factories
Issue Date:
17-Aug-2017
URI:
http://hdl.handle.net/10033/621102
DOI:
10.1186/s12934-017-0756-z
PubMed ID:
28818083
Type:
Article
Language:
en
ISSN:
1475-2859
Appears in Collections:
publications of the department of microbial drugs (MWIS); publications of the department of microbial natural substances ([HIPS]MINS)

Full metadata record

DC FieldValue Language
dc.contributor.authorBeckmann, Amelieen
dc.contributor.authorHüttel, Stephanen
dc.contributor.authorSchmitt, Viktoriaen
dc.contributor.authorMüller, Rolfen
dc.contributor.authorStadler, Marcen
dc.date.accessioned2017-09-11T12:23:25Z-
dc.date.available2017-09-11T12:23:25Z-
dc.date.issued2017-08-17-
dc.identifier.citationOptimization of the biotechnological production of a novel class of anti-MRSA antibiotics from Chitinophaga sancti. 2017, 16 (1):143 Microb. Cell Fact.en
dc.identifier.issn1475-2859-
dc.identifier.pmid28818083-
dc.identifier.doi10.1186/s12934-017-0756-z-
dc.identifier.urihttp://hdl.handle.net/10033/621102-
dc.description.abstractRecently, the discovery of the elansolids, a group of macrolides, was reported. The molecules show activity against methicillin-resistant Staphylococcus aureus as well as other gram-positive organisms. This fact renders those substances a promising starting point for future chemical development. The active atropisomers A1/A2 are formed by macrolactonization of the biosynthesis product A3 but are prone to ring opening and subsequent formation of several unwanted side products. Recently it could be shown that addition of different nucleophiles to culture extracts of Chitinophaga sancti enable the formation of new stable elansolid derivatives. Furthermore, addition of such a nucleophile directly into the culture led exclusively to formation of a single active elansolid derivative. Due to low product yields, methods for production of gram amounts of these molecules have to be established to enable further development of this promising compound class.en
dc.language.isoenen
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.titleOptimization of the biotechnological production of a novel class of anti-MRSA antibiotics from Chitinophaga sancti.en
dc.typeArticleen
dc.contributor.departmentHelmholtz-Zentrum für Infektionsforschung GmbH, Inhoffenstr. 7, 38124 Braunschweig, Germany.en
dc.identifier.journalMicrobial cell factoriesen

Related articles on PubMed

This item is licensed under a Creative Commons License
Creative Commons
All Items in HZI are protected by copyright, with all rights reserved, unless otherwise indicated.